Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer

ConclusionsThe PopPK model adequately described lucitanib pharmacokinetics. High between-subject pharmacokinetic variability supports a safety-based dose-titration strategy currently being used in an ongoing clinical study of lucitanib to optimize drug exposure and clinical benefit.Trial RegistrationClinicalTrials.gov Identifier: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746, NCT02109016.

http://link.springer.com/10.1007/s13318-022-00773-w

Source: European Journal of Drug Metabolism and Pharmacokinetics - July 18, 2022 Category: Drugs & Pharmacology Source Type: research